Amicus loses ground to rivals Sanofi and BioMarin in the race to develop drugs for rare, orphan diseases.
If this Kalydeco study is positive, Vertex will be able to market the drug to another 1,100 cystic fibrosis patients.
A heart drug from Anthera and a skin cancer vaccine from Vical caused patients harm, according to results from clinical trials presented Monday.
An FDA panel will decide whether or not recommend the approval of Vanda's tasimelteon to treat a sleep disorder affecting blind people.
Imbruvica will be used to treated mantle cell lymphoma.
Pondering next steps for Sarepta and its Duchenne muscular dystrophy drug eteplirsen.
Sarepta will need to conduct a larger phase III study before seeking eteplirsen approval for Duchenne muscular dystrophy.
Three press releases on Ampion, but investors still can't determine if the drug is effective.
Shire's acquisition centers around Viropharma's Cinryze, which treats hereditary angioedema.
Marc Beer's suggests Juxtapid helps patients live longer, but FDA says the drug does no such thing.